GLP-1 Medications May Quiet the Craving Behind Addiction
A landmark BMJ study published June 3, 2026 found that GLP-1 receptor agonists like semaglutide significantly reduced both the development and severity of substance use disorders in over 600,000 U.S. veterans. Cannabis use disorder risk dropped 14%,…
Modes of cannabis administration, cannabis and tobacco co-use, and associations
This study highlights that adults who co-use cannabis with tobacco are more likely to use combustible methods, leading to worse respiratory outcomes and higher cannabis consumption.
SAMHSA’s 2026 Clinical Guidance for Physicians and Patients on Cannabis Use Disorder
SAMHSA released a formal 2026 advisory instructing primary care physicians to evaluate cannabis use based on clinical signs of harm, not simply patient use. Dr. Caplan breaks down what this federal guidance actually says, where current diagnostic tools…
In the Mix: 10 More Articles — May 20, 2026
This article reviews adolescent cannabis use disorder treatment delays and emerging clinical trends in 2026. It highlights the importance of monitoring cannabis mental health impacts in youth. Clinicians should consider regulatory developments affecting…
Teen cannabis use alters brain development and raises addiction risk – News-Medical.Net
Cannabis effects on teenage brain development present unique clinical concerns during critical neurodevelopmental windows. Adolescent cannabis exposure can disrupt normal brain maturation and increase addiction risk. Understanding these developmental…
Cannabis Use Disorder Strongly Linked to Major Depression, New Review Finds
✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. Mental HealthResearchTHCCannabis Use DisorderDepressionSafetyNeurology Why This Matters Clinicians treating patients…
Teen Substance Use Treatment Evidence
This Evidence Watch article reviews a 2026 systematic evidence update on adolescent substance use treatment. The review found that family-based therapy, CBT, motivational approaches, and multicomponent behavioral care remain the best-supported outpatient…
I didn’t think I could get addicted to weed. I was wrong – and I’m not alone – The Guardian
✦ New CED Clinical Relevance#65 Notable Clinical InterestEmerging findings or policy developments worth monitoring closely. Mental HealthTHCResearchSafetyAddiction Why This MattersClinicians need to recognize that cannabis use disorder is a genuine…
Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia
A novel clinical trial is investigating tDCS cannabis use disorder schizophrenia treatment, targeting specific brain circuits involved in addiction and cognitive control. This innovative approach addresses the challenging dual diagnosis where traditional…
Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder
Groundbreaking research is investigating adolescent cannabis use disorder biomarkers in the endocannabinoid and opioid systems. This study could identify predictive markers for relapse risk in young patients. The findings may transform how clinicians…
